Correlation Between 23Andme Holding and Cyclacel Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both 23Andme Holding and Cyclacel Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 23Andme Holding and Cyclacel Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between 23Andme Holding Co and Cyclacel Pharmaceuticals, you can compare the effects of market volatilities on 23Andme Holding and Cyclacel Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 23Andme Holding with a short position of Cyclacel Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of 23Andme Holding and Cyclacel Pharmaceuticals.

Diversification Opportunities for 23Andme Holding and Cyclacel Pharmaceuticals

0.73

Correlation Coefficient

23Andme Holding  Cyclacel Pharmaceuticals

Poor diversification

The 3 months correlation between 23Andme and Cyclacel is 0.73. Overlapping area represents the amount of risk that can be diversified away by holding 23Andme Holding Co and Cyclacel Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclacel Pharmaceuticals and 23Andme Holding is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 23Andme Holding Co are associated (or correlated) with Cyclacel Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclacel Pharmaceuticals has no effect on the direction of 23Andme Holding i.e., 23Andme Holding and Cyclacel Pharmaceuticals go up and down completely randomly.

Pair Corralation between 23Andme Holding and Cyclacel Pharmaceuticals

Allowing for the 90-day total investment horizon 23Andme Holding Co is expected to under-perform the Cyclacel Pharmaceuticals. In addition to that, 23Andme Holding is 2.14 times more volatile than Cyclacel Pharmaceuticals. It trades about -0.15 of its total potential returns per unit of risk. Cyclacel Pharmaceuticals is currently generating about -0.03 per unit of volatility. If you would invest  37.00  in Cyclacel Pharmaceuticals on December 28, 2024 and sell it today you would lose (6.00) from holding Cyclacel Pharmaceuticals or give up 16.22% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	98.36%
Values	Daily Returns

23Andme Holding Co  vs.  Cyclacel Pharmaceuticals

23Andme Holding

Risk-Adjusted Performance

Very Weak

Over the last 90 days 23Andme Holding Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Cyclacel Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Pair Trading with 23Andme Holding and Cyclacel Pharmaceuticals

The main advantage of trading using opposite 23Andme Holding and Cyclacel Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 23Andme Holding position performs unexpectedly, Cyclacel Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will offset losses from the drop in Cyclacel Pharmaceuticals' long position.

The idea behind 23Andme Holding Co and Cyclacel Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.